Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Targeting the cancer mutanome of breast cancer.

Radvanyi LG.

Nat Med. 2018 Jun;24(6):703-704. doi: 10.1038/s41591-018-0065-z. No abstract available.

PMID:
29867234
2.

Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.

Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Gonzalez AM, Toth CL, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn C, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, Davies MA, Diab A, Glitza IC, Tawbi H, Wong MK, Cain S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Wargo JA, Radvanyi LG, Torres-Cabala CA, Beroukhim R, Hwu P, Amaria RN, Bernatchez C.

Clin Cancer Res. 2018 Sep 15;24(18):4416-4428. doi: 10.1158/1078-0432.CCR-17-3649. Epub 2018 May 30.

PMID:
29848573
3.

Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma.

Tavera RJ, Forget MA, Kim YU, Sakellariou-Thompson D, Creasy CA, Bhatta A, Fulbright OJ, Ramachandran R, Thorsen ST, Flores E, Wahl A, Gonzalez AM, Toth C, Wardell S, Mansaray R, Radvanyi LG, Gombos DS, Patel SP, Hwu P, Amaria RN, Bernatchez C, Haymaker C.

J Immunother. 2018 May 11. doi: 10.1097/CJI.0000000000000230. [Epub ahead of print]

PMID:
29757889
4.

Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β.

Lan Y, Zhang D, Xu C, Hance KW, Marelli B, Qi J, Yu H, Qin G, Sircar A, Hernández VM, Jenkins MH, Fontana RE, Deshpande A, Locke G, Sabzevari H, Radvanyi L, Lo KM.

Sci Transl Med. 2018 Jan 17;10(424). pii: eaan5488. doi: 10.1126/scitranslmed.aan5488.

PMID:
29343622
5.

Single-cell profiling of dynamic cytokine secretion and the phenotype of immune cells.

An X, Sendra VG, Liadi I, Ramesh B, Romain G, Haymaker C, Martinez-Paniagua M, Lu Y, Radvanyi LG, Roysam B, Varadarajan N.

PLoS One. 2017 Aug 24;12(8):e0181904. doi: 10.1371/journal.pone.0181904. eCollection 2017.

6.

Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter.

Ritthipichai K, Haymaker CL, Martinez M, Aschenbrenner A, Yi X, Zhang M, Kale C, Vence LM, Roszik J, Hailemichael Y, Overwijk WW, Varadarajan N, Nurieva R, Radvanyi LG, Hwu P, Bernatchez C.

Clin Cancer Res. 2017 Oct 15;23(20):6151-6164. doi: 10.1158/1078-0432.CCR-16-1217. Epub 2017 Jul 28.

PMID:
28754817
7.

Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function.

Lee YH, Martin-Orozco N, Zheng P, Li J, Zhang P, Tan H, Park HJ, Jeong M, Chang SH, Kim BS, Xiong W, Zang W, Guo L, Liu Y, Dong ZJ, Overwijk WW, Hwu P, Yi Q, Kwak L, Yang Z, Mak TW, Li W, Radvanyi LG, Ni L, Liu D, Dong C.

Cell Res. 2017 Aug;27(8):1034-1045. doi: 10.1038/cr.2017.90. Epub 2017 Jul 7.

8.

Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models.

Xu C, Zhang Y, Rolfe PA, Hernández VM, Guzman W, Kradjian G, Marelli B, Qin G, Qi J, Wang H, Yu H, Tighe R, Lo KM, English JM, Radvanyi L, Lan Y.

Clin Cancer Res. 2017 Oct 1;23(19):5869-5880. doi: 10.1158/1078-0432.CCR-17-0483. Epub 2017 Jul 5.

PMID:
28679778
9.

Downregulation of Human Endogenous Retrovirus Type K (HERV-K) Viral env RNA in Pancreatic Cancer Cells Decreases Cell Proliferation and Tumor Growth.

Li M, Radvanyi L, Yin B, Li J, Chivukula R, Lin K, Lu Y, Shen J, Chang DZ, Li D, Johanning GL, Wang-Johanning F.

Clin Cancer Res. 2017 Oct 1;23(19):5892-5911. doi: 10.1158/1078-0432.CCR-17-0001. Epub 2017 Jul 5.

10.

4-1BB-Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T Cells.

Harao M, Forget MA, Roszik J, Gao H, Babiera GV, Krishnamurthy S, Chacon JA, Li S, Mittendorf EA, DeSnyder SM, Rockwood KF, Bernatchez C, Ueno NT, Radvanyi LG, Vence L, Haymaker C, Reuben JM.

Cancer Immunol Res. 2017 Jun;5(6):439-445. doi: 10.1158/2326-6066.CIR-16-0364. Epub 2017 May 4.

11.

IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation.

Sim GC, Liu C, Wang E, Liu H, Creasy C, Dai Z, Overwijk WW, Roszik J, Marincola F, Hwu P, Grimm E, Radvanyi L.

Cancer Immunol Res. 2016 Nov;4(11):983-994. Epub 2016 Oct 3.

12.

Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set.

Roszik J, Haydu LE, Hess KR, Oba J, Joon AY, Siroy AE, Karpinets TV, Stingo FC, Baladandayuthapani V, Tetzlaff MT, Wargo JA, Chen K, Forget MA, Haymaker CL, Chen JQ, Meric-Bernstam F, Eterovic AK, Shaw KR, Mills GB, Gershenwald JE, Radvanyi LG, Hwu P, Futreal PA, Gibbons DL, Lazar AJ, Bernatchez C, Davies MA, Woodman SE.

BMC Med. 2016 Oct 25;14(1):168.

13.

Defective STAT1 activation associated with impaired IFN-γ production in NK and T lymphocytes from metastatic melanoma patients treated with IL-2.

Sim GC, Wu S, Jin L, Hwu P, Radvanyi LG.

Oncotarget. 2016 Jun 14;7(24):36074-36091. doi: 10.18632/oncotarget.8683.

14.

The beneficial effects of a gas-permeable flask for expansion of Tumor-Infiltrating lymphocytes as reflected in their mitochondrial function and respiration capacity.

Forget MA, Haymaker C, Dennison JB, Toth C, Maiti S, Fulbright OJ, Cooper LJ, Hwu P, Radvanyi LG, Bernatchez C.

Oncoimmunology. 2015 Jun 5;5(2):e1057386. eCollection 2016 Feb.

15.

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.

Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres-Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC, Cascone T, Li HS, Kwong LN, Heffernan TP, Hu J, Bassett RL Jr, Bosenberg MW, Woodman SE, Overwijk WW, Lizée G, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi L, Davies MA, Hwu P.

Cancer Discov. 2016 Feb;6(2):202-16. doi: 10.1158/2159-8290.CD-15-0283. Epub 2015 Dec 8.

16.

Tumor-Infiltrating Lymphocyte Therapy: Addressing Prevailing Questions.

Radvanyi LG.

Cancer J. 2015 Nov-Dec;21(6):450-64. doi: 10.1097/PPO.0000000000000162. Review.

PMID:
26588676
17.

Triggering co-stimulation directly in melanoma tumor fragments drives CD8+ tumor-infiltrating lymphocyte expansion with improved effector-memory properties.

Chacon JA, Sarnaik AA, Pilon-Thomas S, Radvanyi L.

Oncoimmunology. 2015 Jul 1;4(12):e1040219. eCollection 2015 Dec.

18.

BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties.

Haymaker CL, Wu RC, Ritthipichai K, Bernatchez C, Forget MA, Chen JQ, Liu H, Wang E, Marincola F, Hwu P, Radvanyi LG.

Oncoimmunology. 2015 Mar 16;4(8):e1014246. eCollection 2015 Aug.

19.

PD-L1 expression and prognostic impact in glioblastoma.

Nduom EK, Wei J, Yaghi NK, Huang N, Kong LY, Gabrusiewicz K, Ling X, Zhou S, Ivan C, Chen JQ, Burks JK, Fuller GN, Calin GA, Conrad CA, Creasy C, Ritthipichai K, Radvanyi L, Heimberger AB.

Neuro Oncol. 2016 Feb;18(2):195-205. doi: 10.1093/neuonc/nov172. Epub 2015 Aug 30.

20.

Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report.

Glitza IC, Haymaker C, Bernatchez C, Vence L, Rohlfs M, Richard J, Lacey C, Mansaray R, Fulbright OJ, Ramachandran R, Toth C, Wardell S, Patel SP, Woodman SE, Hwu WJ, Radvanyi LG, Davies MA, Papadopoulos NE, Hwu P.

Cancer Immunol Res. 2015 Nov;3(11):1201-6. doi: 10.1158/2326-6066.CIR-15-0071. Epub 2015 Jul 27.

21.

Multicystic dedifferentiated retroperitoneal liposarcoma: tumour cyst fluid analysis and implications for management.

Khoury M, Sim GC, Harao M, Radvanyi L, Amini B, Benjamin RS, Pisters PW, Pollock RE, Tseng WW.

BMJ Case Rep. 2015 Jul 8;2015. pii: bcr2015211218. doi: 10.1136/bcr-2015-211218.

22.

BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma.

Bradley SD, Chen Z, Melendez B, Talukder A, Khalili JS, Rodriguez-Cruz T, Liu S, Whittington M, Deng W, Li F, Bernatchez C, Radvanyi LG, Davies MA, Hwu P, Lizée G.

Cancer Immunol Res. 2015 Jun;3(6):602-9. doi: 10.1158/2326-6066.CIR-15-0030. Epub 2015 Mar 20.

23.

Analysis of the intratumoral adaptive immune response in well differentiated and dedifferentiated retroperitoneal liposarcoma.

Tseng WW, Malu S, Zhang M, Chen J, Sim GC, Wei W, Ingram D, Somaiah N, Lev DC, Pollock RE, Lizée G, Radvanyi L, Hwu P.

Sarcoma. 2015;2015:547460. doi: 10.1155/2015/547460. Epub 2015 Jan 29.

24.

Peptide-based vaccination and induction of CD8+ T-cell responses against tumor antigens in breast cancer.

Harao M, Mittendorf EA, Radvanyi LG.

BioDrugs. 2015 Feb;29(1):15-30. doi: 10.1007/s40259-014-0114-1. Review.

PMID:
25523015
25.

Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy.

Chacon JA, Sarnaik AA, Chen JQ, Creasy C, Kale C, Robinson J, Weber J, Hwu P, Pilon-Thomas S, Radvanyi L.

Clin Cancer Res. 2015 Feb 1;21(3):611-21. doi: 10.1158/1078-0432.CCR-14-1934. Epub 2014 Dec 3.

26.

Cytotoxicity of human endogenous retrovirus K-specific T cells toward autologous ovarian cancer cells.

Rycaj K, Plummer JB, Yin B, Li M, Garza J, Radvanyi L, Ramondetta LM, Lin K, Johanning GL, Tang DG, Wang-Johanning F.

Clin Cancer Res. 2015 Jan 15;21(2):471-83. doi: 10.1158/1078-0432.CCR-14-0388. Epub 2014 Nov 4.

27.

Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma.

Forget MA, Malu S, Liu H, Toth C, Maiti S, Kale C, Haymaker C, Bernatchez C, Huls H, Wang E, Marincola FM, Hwu P, Cooper LJ, Radvanyi LG.

J Immunother. 2014 Nov-Dec;37(9):448-60. doi: 10.1097/CJI.0000000000000056.

28.

The IL-2 cytokine family in cancer immunotherapy.

Sim GC, Radvanyi L.

Cytokine Growth Factor Rev. 2014 Aug;25(4):377-90. doi: 10.1016/j.cytogfr.2014.07.018. Epub 2014 Aug 1. Review.

PMID:
25200249
29.

Tumor-infiltrating lymphocyte therapy for melanoma: rationale and issues for further clinical development.

Sim GC, Chacon J, Haymaker C, Ritthipichai K, Singh M, Hwu P, Radvanyi L.

BioDrugs. 2014 Oct;28(5):421-37. doi: 10.1007/s40259-014-0097-y. Review.

PMID:
24890028
30.

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial.

Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS.

Lancet Oncol. 2014 Jan;15(1):69-77. doi: 10.1016/S1470-2045(13)70551-5. Epub 2013 Dec 11.

31.

An Antibody-based Blood Test Utilizing a Panel of Biomarkers as a New Method for Improved Breast Cancer Diagnosis.

Yahalom G, Weiss D, Novikov I, Bevers TB, Radvanyi LG, Liu M, Piura B, Iacobelli S, Sandri MT, Cassano E, Allweis TM, Bitterman A, Engelman P, Vence LM, Rosenberg MM.

Biomark Cancer. 2013 Nov 19;5:71-80. doi: 10.4137/BIC.S13236. eCollection 2013.

32.

Continuous 4-1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy.

Chacon JA, Pilon-Thomas S, Sarnaik AA, Radvanyi LG.

Oncoimmunology. 2013 Sep 1;2(9):e25581. Epub 2013 Jul 3.

33.

IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients.

Sim GC, Martin-Orozco N, Jin L, Yang Y, Wu S, Washington E, Sanders D, Lacey C, Wang Y, Vence L, Hwu P, Radvanyi L.

J Clin Invest. 2014 Jan;124(1):99-110.

34.

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--letter.

Radvanyi L, Pilon-Thomas S, Peng W, Sarnaik A, Mulé JJ, Weber J, Hwu P.

Clin Cancer Res. 2013 Oct 1;19(19):5541. doi: 10.1158/1078-0432.CCR-13-1054. Epub 2013 Sep 18. No abstract available.

35.

Immunotherapy exposes cancer stem cell resistance and a new synthetic lethality.

Radvanyi L.

Mol Ther. 2013 Aug;21(8):1472-4. doi: 10.1038/mt.2013.160. No abstract available.

36.

Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), a GATA family transcription factor, in early-stage breast cancer.

Chen JQ, Bao Y, Lee J, Murray JL, Litton JK, Xiao L, Zhou R, Wu Y, Shen XY, Zhang H, Sahin AA, Katz RL, Bondy ML, Berinstein NL, Hortobagyi GN, Radvanyi LG.

Ann Oncol. 2013 Oct;24(10):2534-42. doi: 10.1093/annonc/mdt190. Epub 2013 May 31.

37.

Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccination.

Vence LM, Wang C, Pappu H, Anson RE, Patel TA, Miller P, Bassett R, Lizee G, Overwijk WW, Komanduri K, Benjamin C, Alvarado G, Patel SP, Kim K, Papadopoulos NE, Bedikian AY, Homsi J, Hwu WJ, Boyd R, Radvanyi L, Hwu P.

J Immunother. 2013 May;36(4):276-86. doi: 10.1097/CJI.0b013e31829419f3.

38.

Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.

Chacon JA, Wu RC, Sukhumalchandra P, Molldrem JJ, Sarnaik A, Pilon-Thomas S, Weber J, Hwu P, Radvanyi L.

PLoS One. 2013;8(4):e60031. doi: 10.1371/journal.pone.0060031. Epub 2013 Apr 1.

39.

BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice.

Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, Chen JQ, Li HS, Watowich SS, Yang Y, Tompers Frederick D, Cooper ZA, Mbofung RM, Whittington M, Flaherty KT, Woodman SE, Davies MA, Radvanyi LG, Overwijk WW, Lizée G, Hwu P.

Clin Cancer Res. 2013 Jan 15;19(2):393-403. doi: 10.1158/1078-0432.CCR-12-1626. Epub 2012 Nov 30.

40.

New insights on the role of CD8(+)CD57(+) T-cells in cancer.

Wu RC, Hwu P, Radvanyi LG.

Oncoimmunology. 2012 Sep 1;1(6):954-956.

41.

Broad cross-presentation of the hematopoietically derived PR1 antigen on solid tumors leads to susceptibility to PR1-targeted immunotherapy.

Alatrash G, Mittendorf EA, Sergeeva A, Sukhumalchandra P, Qiao N, Zhang M, St John LS, Ruisaard K, Haugen CE, Al-Atrache Z, Jakher H, Philips AV, Ding X, Chen JQ, Wu Y, Patenia RS, Bernatchez C, Vence LM, Radvanyi LG, Hwu P, Clise-Dwyer K, Ma Q, Lu S, Molldrem JJ.

J Immunol. 2012 Dec 1;189(11):5476-84. doi: 10.4049/jimmunol.1201221. Epub 2012 Oct 26.

42.

Harnessing the power of the immune system to target cancer.

Lizée G, Overwijk WW, Radvanyi L, Gao J, Sharma P, Hwu P.

Annu Rev Med. 2013;64:71-90. doi: 10.1146/annurev-med-112311-083918. Epub 2012 Oct 22. Review.

PMID:
23092383
43.

Spleen cells from young donors eradicate large tumors--letter.

Radvanyi L.

Clin Cancer Res. 2012 Nov 1;18(21):6074-5; author reply 6076. doi: 10.1158/1078-0432.CCR-12-2369. Epub 2012 Oct 15. No abstract available.

44.

Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients.

Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, Wu R, Lizee G, Mahoney S, Alvarado G, Glass M, Johnson VE, McMannis JD, Shpall E, Prieto V, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Patel S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Davies MA, Mansaray R, Fulbright OJ, Toth C, Ramachandran R, Wardell S, Gonzalez A, Hwu P.

Clin Cancer Res. 2012 Dec 15;18(24):6758-70. doi: 10.1158/1078-0432.CCR-12-1177. Epub 2012 Oct 2.

45.

Advances in the development of cancer immunotherapies.

Gao J, Bernatchez C, Sharma P, Radvanyi LG, Hwu P.

Trends Immunol. 2013 Feb;34(2):90-8. doi: 10.1016/j.it.2012.08.004. Epub 2012 Sep 30. Review.

46.

MUC1 glycopeptide epitopes predicted by computational glycomics.

Song W, Delyria ES, Chen J, Huang W, Lee JS, Mittendorf EA, Ibrahim N, Radvanyi LG, Li Y, Lu H, Xu H, Shi Y, Wang LX, Ross JA, Rodrigues SP, Almeida IC, Yang X, Qu J, Schocker NS, Michael K, Zhou D.

Int J Oncol. 2012 Dec;41(6):1977-84. doi: 10.3892/ijo.2012.1645. Epub 2012 Sep 27.

47.

PD-1 and BTLA and CD8(+) T-cell "exhaustion" in cancer: "Exercising" an alternative viewpoint.

Haymaker C, Wu R, Bernatchez C, Radvanyi L.

Oncoimmunology. 2012 Aug 1;1(5):735-738.

48.

PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines.

Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, Yagita H, Overwijk WW, Lizée G, Radvanyi L, Hwu P.

Cancer Res. 2012 Oct 15;72(20):5209-18. doi: 10.1158/0008-5472.CAN-12-1187. Epub 2012 Aug 20.

49.

Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: role of inflammatory signaling.

Cohen L, Cole SW, Sood AK, Prinsloo S, Kirschbaum C, Arevalo JM, Jennings NB, Scott S, Vence L, Wei Q, Kentor D, Radvanyi L, Tannir N, Jonasch E, Tamboli P, Pisters L.

PLoS One. 2012;7(8):e42324. doi: 10.1371/journal.pone.0042324. Epub 2012 Aug 1.

50.

Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma.

Khalili JS, Liu S, Rodríguez-Cruz TG, Whittington M, Wardell S, Liu C, Zhang M, Cooper ZA, Frederick DT, Li Y, Zhang M, Joseph RW, Bernatchez C, Ekmekcioglu S, Grimm E, Radvanyi LG, Davis RE, Davies MA, Wargo JA, Hwu P, Lizée G.

Clin Cancer Res. 2012 Oct 1;18(19):5329-40. doi: 10.1158/1078-0432.CCR-12-1632. Epub 2012 Jul 31.

Supplemental Content

Loading ...
Support Center